Algorithm for managing the platelet refractory patient

Journal of Clinical Apheresis

Volumn 12, Issue 1, 1997, Pages 4-9

  Slichter, Sherrill J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

Author keywords

alloantibodies; platelet immunology; platelet refractoriness; platelet transfusion; platelets

Indexed keywords

BLOOD COMPATIBILITY; BLOOD GROUP ABO SYSTEM; HUMAN; RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; TREATMENT PLANNING;

ALGORITHMS; BLOOD GROUPING AND CROSSMATCHING; HUMANS; PLATELET TRANSFUSION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030970816     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(1997)12:1<4::AID-JCA2>3.0.CO;2-E     Document Type: Review

References (40)

1. Aster RH: Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 26:732, 1965.
2. Heal JM, Blumberg N, Masel D: An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 70:23, 1987.
3. Hogge DE, Thompson BW, Schiffer CA: Platelet storage for 7 days in second-generation blood bags. Transfusion 26:131, 1986.
4. Schiffer CA, Lee EJ, Ness PM, Reilly J: Clinical evaluation of platelet concentrates stored for one to five days. Blood 67:1591, 1986.
5. Lazarus HM, Herzig RH, Warm SE, Fishman FJ: Transfusion experience with platelet concentrates stored for 24 to 72 hours at 22°C. Transfusion 22:39, 1982.
6. Peter-Salonen K, Bucher U, Nydegger UE: Comparison of post-transfusion recoveries achieved with either fresh or stored platelet concentrates. Blut 54:207, 1987.
7. Duguid JKM, Carr R, Jenkins JA, Hutton JL, Lucas GF, Davies JM: Clinical evaluation of the effects of storage time and irradiation on transfused platelets. Vox Sang 60:151, 1991.
8. Leach MF, AuBuchon JP: Effect of storage time on clinical efficacy of single-donor platelet units. Transfusion 33:661, 1993.
9. Holme S, Heaton WA, Courtright M: Platelet storage lesion in second-generation containers: correlation with platelet ATP levels. Vox Sang 53:2142, 1987.
10. Snyder EL, Ezekowitz M, Aster R, et al.: Extended storage of platelets in a new plastic container: II. In vivo response to infusion of platelets stored for 5 days. Transfusion 25:209, 1985.
11. Rock G, Tittley P, McCombie N: 5-day storage of single-donor platelets obtained using a blood cell separator. Transfusion 29: 288, 1989.
12. Shanwell A, Gulliksson H, Berg BK, et al.: Evaluation of platelets prepared by apheresis and stored for 5 days. In vitro and in vivo studies. Transfusion 29:783, 1989.
13. Yankee RA, Grumet FC, Rogentine GN: Platelet transfusion therapy. The selection of compatible donors for refractory patients by lymphocyte HLA typing. N Engl J Med 281:1208, 1969.
14. Duquesnoy RJ, Filip DJ, Rodey GE, et al.: Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 2:219, 1977.
15. Kickler TS, Nedd PM, Braine HG: Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient. AJCP 90:69, 1988.
16. Rachel JM, Summers TC, Sinor LT, Plapp FV: Use of a solid phase red blood cell adherence method for pre-transfusion platelet compatibility testing. AJCP 90:63, 1988.
17. Freedman J, Hooi C, Garvey MB: Prospective platelet crossmatching for selection of compatible random donors. Br J Haematol 56:9, 1984.
18. Friedberg RC, Donnally SF, Boyd JC, Lloyd SG, Mintz PD: Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 81:3428, 1993.
19. Bishop JF, McGrath K, Wolf MM, et al.: Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 71:383, 1988.
20. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 66:200, 1994.
21. Alcorta I, Pereira A, Ordinas A: Clinical and laboratory factors associated with platelet transfusion refractoriness: A case-control study. Br J Haematol 93:220, 1996.
22. Yankee RA, Graff KS, Dowling R, et al.: Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med 288:760, 1973.
23. Hussein MA, Lee EJ, Fletcher R, Schiffer CA: The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood 87:3959, 1996.
24. Kickler TS, Braine H, Ness PM: The predictive value of crossmatching platelet transfusions for alloimmunized patients. Transfusion 25:385, 1985.
25. McFarland JG, Aster RH: Evaluation of four methods for platelet compatibility testing. Blood 69:1425, 1987.
26. Kickler TS, Braine HG, Ness PM, et al.: A radiolabeled antiglobulin test for crossmatching platelet transfusions. Blood 61:238, 1983.
27. Freedman J, Garvey MB, Salomon de Friedberg Z, et al.: Random donor platelet crossmatching: Comparison of four platelet antibody detection methods. Am J Hematol 28:1, 1988.
28. Gates K, MacPherson BR: Retrospective evaluation of flow cytometry as a platelet crossmatching procedure. Cytometry 18:123, 1994.
29. Warfolk LA, MacPherson BR: The detection of platelet alloantibodies by flow cytometry. Transfusion 31:340, 1991.
30. von dem Borne AEGKr, Ouwehand WH, Kruijpers RWAM. Theoretic and practical aspects of platelet crossmatching. Transfus Med Rev 4:265, 1990.
31. Freedman J, Gafni A, Garvey MB, et al.: A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 29:201, 1989.
32. Kickler T, Kennedy SD, Braine HG: Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 30:622, 1990.
33. Uhrynowska M, Zupanska B: Platelet-specific antibodies in transfused patients. Eur J Haematol 56:248, 1996.
34. Norol F, Kuentz M, Cordonnier C, et al.: Influence of clinical status on the efficacy of stored platelet transfusions. Br J Haematol 86:125, 1994.
35. Kitchens CS, Pendergast JF: Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. Blood 67:203, 1986.
36. Haselton FR, Alexander JS: Platelets and a platelet-released factor enhance endothelial barrier. Am J Physiol 263:L670, 1992.
37. Bartholomew JR, Salgia R, Bell WR: Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 149:1959, 1989.
38. Gardner FH, Helmer RE: Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 243:35, 1980.
39. Garewal HS, Durie BGM: Anti-fibrinolytic therapy as aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand J Haematol 35:497, 1985.
40. Ben-Bassat I, Douer D, Ramot B: Tranexamic acid in acute myeloid leukemia: Possible reduction of platelet transfusions. Eur J Haematol 45:86, 1990.